BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ma X, Pan X, Wei Y, Tan B, Yang L, Ren H, Qian M, Du B. Chemotherapy-induced uridine diphosphate release promotes breast cancer metastasis through P2Y6 activation. Oncotarget 2016;7:29036-50. [PMID: 27074554 DOI: 10.18632/oncotarget.8664] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu P, Wang C, Xiang W, Liang Y, Li Y, Zhang X, Guo C, Liu M, Shi Y, Ye X, Dang Y. P2RY6 has a critical role in mouse skin carcinogenesis by regulating the YAP and β-catenin signaling pathways. J Invest Dermatol 2022:S0022-202X(22)00202-0. [PMID: 35304248 DOI: 10.1016/j.jid.2022.02.017] [Reference Citation Analysis]
2 Umar MI, Hassan W, Murtaza G, Buabeid M, Arafa E, Irfan HM, Asmawi MZ, Huang X. The Adipokine Component in the Molecular Regulation of Cancer Cell Survival, Proliferation and Metastasis. Pathol Oncol Res 2021;27:1609828. [PMID: 34588926 DOI: 10.3389/pore.2021.1609828] [Reference Citation Analysis]
3 Alvarez CL, Troncoso MF, Espelt MV. Extracellular ATP and adenosine in tumor microenvironment: Roles in epithelial-mesenchymal transition, cell migration, and invasion. J Cell Physiol 2021. [PMID: 34514618 DOI: 10.1002/jcp.30580] [Reference Citation Analysis]
4 Reyna-Jeldes M, Díaz-Muñoz M, Madariaga JA, Coddou C, Vázquez-Cuevas FG. Autocrine and paracrine purinergic signaling in the most lethal types of cancer. Purinergic Signal 2021. [PMID: 33982134 DOI: 10.1007/s11302-021-09785-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 de Araújo JB, Kerkhoff VV, de Oliveira Maciel SFV, de Resende E Silva DT. Targeting the purinergic pathway in breast cancer and its therapeutic applications. Purinergic Signal 2021;17:179-200. [PMID: 33576905 DOI: 10.1007/s11302-020-09760-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Sharma S, Kalra H, Akundi RS. Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2. Front Pharmacol 2020;11:617211. [PMID: 33584298 DOI: 10.3389/fphar.2020.617211] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Woods LT, Forti KM, Shanbhag VC, Camden JM, Weisman GA. P2Y receptors for extracellular nucleotides: Contributions to cancer progression and therapeutic implications. Biochem Pharmacol 2021;187:114406. [PMID: 33412103 DOI: 10.1016/j.bcp.2021.114406] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Arnaud-Sampaio VF, Rabelo ILA, Bento CA, Glaser T, Bezerra J, Coutinho-Silva R, Ulrich H, Lameu C. Using Cytometry for Investigation of Purinergic Signaling in Tumor-Associated Macrophages. Cytometry A 2020;97:1109-26. [PMID: 32633884 DOI: 10.1002/cyto.a.24035] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Girard M, Dagenais Bellefeuille S, Eiselt É, Brouillette R, Placet M, Arguin G, Longpré JM, Sarret P, Gendron FP. The P2Y6 receptor signals through Gαq /Ca2+ /PKCα and Gα13 /ROCK pathways to drive the formation of membrane protrusions and dictate cell migration. J Cell Physiol 2020;235:9676-90. [PMID: 32420639 DOI: 10.1002/jcp.29779] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
10 Wen RX, Shen H, Huang SX, Wang LP, Li ZW, Peng P, Mamtilahun M, Tang YH, Shen FX, Tian HL, Yang GY, Zhang ZJ. P2Y6 receptor inhibition aggravates ischemic brain injury by reducing microglial phagocytosis. CNS Neurosci Ther 2020;26:416-29. [PMID: 32154670 DOI: 10.1111/cns.13296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
11 Qin J, Zhang Z, Fu Z, Ren H, Liu M, Qian M, Du B. The UDP/P2y6 axis promotes lung metastasis of melanoma by remodeling the premetastatic niche. Cell Mol Immunol 2020;17:1269-71. [PMID: 32144377 DOI: 10.1038/s41423-020-0392-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Jiang MJ, Gu DN, Dai JJ, Huang Q, Tian L. Dark Side of Cytotoxic Therapy: Chemoradiation-Induced Cell Death and Tumor Repopulation. Trends Cancer 2020;6:419-31. [PMID: 32348737 DOI: 10.1016/j.trecan.2020.01.018] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
13 Bellefeuille SD, Molle CM, Gendron FP. Reviewing the role of P2Y receptors in specific gastrointestinal cancers. Purinergic Signal 2019;15:451-63. [PMID: 31478181 DOI: 10.1007/s11302-019-09678-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
14 Ma Y, Pitt JM, Li Q, Yang H. The renaissance of anti-neoplastic immunity from tumor cell demise. Immunol Rev 2017;280:194-206. [PMID: 29027231 DOI: 10.1111/imr.12586] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 6.5] [Reference Citation Analysis]
15 Rafehi M, Müller CE. Tools and drugs for uracil nucleotide-activated P2Y receptors. Pharmacol Ther 2018;190:24-80. [PMID: 29660366 DOI: 10.1016/j.pharmthera.2018.04.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 5.8] [Reference Citation Analysis]
16 Placet M, Arguin G, Molle CM, Babeu JP, Jones C, Carrier JC, Robaye B, Geha S, Boudreau F, Gendron FP. The G protein-coupled P2Y₆ receptor promotes colorectal cancer tumorigenesis by inhibiting apoptosis. Biochim Biophys Acta Mol Basis Dis 2018;1864:1539-51. [PMID: 29454075 DOI: 10.1016/j.bbadis.2018.02.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
17 Burnstock G. Purinergic Signalling: Therapeutic Developments. Front Pharmacol 2017;8:661. [PMID: 28993732 DOI: 10.3389/fphar.2017.00661] [Cited by in Crossref: 170] [Cited by in F6Publishing: 164] [Article Influence: 34.0] [Reference Citation Analysis]
18 Toti KS, Jain S, Ciancetta A, Balasubramanian R, Chakraborty S, Surujdin R, Shi ZD, Jacobson KA. Pyrimidine Nucleotides Containing a (S)-Methanocarba Ring as P2Y6 Receptor Agonists. Medchemcomm 2017;8:1897-908. [PMID: 29423136 DOI: 10.1039/C7MD00397H] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
19 Martínez-Ramírez AS, Díaz-Muñoz M, Butanda-Ochoa A, Vázquez-Cuevas FG. Nucleotides and nucleoside signaling in the regulation of the epithelium to mesenchymal transition (EMT). Purinergic Signal 2017;13:1-12. [PMID: 27900516 DOI: 10.1007/s11302-016-9550-3] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 4.3] [Reference Citation Analysis]